Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: Diagnosis, natural history, and risk stratification

Paolo Strati, Tait D. Shanafelt

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Monoclonal B lymphocytosis (MBL) is defined as the presence of a clonal B-cell population in the peripheral blood with fewer than 5 × 10<sup>9</sup>/L B-cells and no other signs of a lymphoproliferative disorder. The majority of cases of MBL have the immunophenotype of chronic lymphocytic leukemia (CLL). MBL can be categorized as either low count or high count based on whether the B-cell count is above or below 0.5 × 10<sup>9</sup>/L. Low-count MBL can be detected in ∼5% of adults over the age of 40 years when assessed using standard-sensitivity flow cytometry assays. A number of biological and genetic characteristics distinguish low-count from high-count MBL. Whereas low-count MBL rarely progresses to CLL, high-count MBL progresses to CLL requiring therapy at a rate of 1% to 2% per year. High-count MBL is distinguished from Rai 0 CLL based on whether the B-cell count is above or below 5 × 10<sup>9</sup>/L. Although individuals with both high-count MBL and CLL Rai stage 0 are at increased risk of infections and second cancers, the risk of progression requiring treatment and the potential to shorten life expectancy are greater for CLL. This review highlights challenging questions regarding the classification, risk stratification, management, and supportive care of patients with MBL and CLL.

Original languageEnglish (US)
Pages (from-to)454-462
Number of pages9
JournalBlood
Volume126
Issue number4
DOIs
StatePublished - Jul 23 2015

Fingerprint

Lymphocytosis
B-Cell Chronic Lymphocytic Leukemia
Natural History
B-Lymphocytes
Cells
Flow cytometry
Assays
Blood
Cell Count
Second Primary Neoplasms
Lymphoproliferative Disorders
Risk Management
Life Expectancy
Patient Care
Flow Cytometry

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia : Diagnosis, natural history, and risk stratification. / Strati, Paolo; Shanafelt, Tait D.

In: Blood, Vol. 126, No. 4, 23.07.2015, p. 454-462.

Research output: Contribution to journalArticle

@article{73f8dca7d51d4d30b9daf9e614a32ade,
title = "Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: Diagnosis, natural history, and risk stratification",
abstract = "Monoclonal B lymphocytosis (MBL) is defined as the presence of a clonal B-cell population in the peripheral blood with fewer than 5 × 109/L B-cells and no other signs of a lymphoproliferative disorder. The majority of cases of MBL have the immunophenotype of chronic lymphocytic leukemia (CLL). MBL can be categorized as either low count or high count based on whether the B-cell count is above or below 0.5 × 109/L. Low-count MBL can be detected in ∼5{\%} of adults over the age of 40 years when assessed using standard-sensitivity flow cytometry assays. A number of biological and genetic characteristics distinguish low-count from high-count MBL. Whereas low-count MBL rarely progresses to CLL, high-count MBL progresses to CLL requiring therapy at a rate of 1{\%} to 2{\%} per year. High-count MBL is distinguished from Rai 0 CLL based on whether the B-cell count is above or below 5 × 109/L. Although individuals with both high-count MBL and CLL Rai stage 0 are at increased risk of infections and second cancers, the risk of progression requiring treatment and the potential to shorten life expectancy are greater for CLL. This review highlights challenging questions regarding the classification, risk stratification, management, and supportive care of patients with MBL and CLL.",
author = "Paolo Strati and Shanafelt, {Tait D.}",
year = "2015",
month = "7",
day = "23",
doi = "10.1182/blood-2015-02-585059",
language = "English (US)",
volume = "126",
pages = "454--462",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia

T2 - Diagnosis, natural history, and risk stratification

AU - Strati, Paolo

AU - Shanafelt, Tait D.

PY - 2015/7/23

Y1 - 2015/7/23

N2 - Monoclonal B lymphocytosis (MBL) is defined as the presence of a clonal B-cell population in the peripheral blood with fewer than 5 × 109/L B-cells and no other signs of a lymphoproliferative disorder. The majority of cases of MBL have the immunophenotype of chronic lymphocytic leukemia (CLL). MBL can be categorized as either low count or high count based on whether the B-cell count is above or below 0.5 × 109/L. Low-count MBL can be detected in ∼5% of adults over the age of 40 years when assessed using standard-sensitivity flow cytometry assays. A number of biological and genetic characteristics distinguish low-count from high-count MBL. Whereas low-count MBL rarely progresses to CLL, high-count MBL progresses to CLL requiring therapy at a rate of 1% to 2% per year. High-count MBL is distinguished from Rai 0 CLL based on whether the B-cell count is above or below 5 × 109/L. Although individuals with both high-count MBL and CLL Rai stage 0 are at increased risk of infections and second cancers, the risk of progression requiring treatment and the potential to shorten life expectancy are greater for CLL. This review highlights challenging questions regarding the classification, risk stratification, management, and supportive care of patients with MBL and CLL.

AB - Monoclonal B lymphocytosis (MBL) is defined as the presence of a clonal B-cell population in the peripheral blood with fewer than 5 × 109/L B-cells and no other signs of a lymphoproliferative disorder. The majority of cases of MBL have the immunophenotype of chronic lymphocytic leukemia (CLL). MBL can be categorized as either low count or high count based on whether the B-cell count is above or below 0.5 × 109/L. Low-count MBL can be detected in ∼5% of adults over the age of 40 years when assessed using standard-sensitivity flow cytometry assays. A number of biological and genetic characteristics distinguish low-count from high-count MBL. Whereas low-count MBL rarely progresses to CLL, high-count MBL progresses to CLL requiring therapy at a rate of 1% to 2% per year. High-count MBL is distinguished from Rai 0 CLL based on whether the B-cell count is above or below 5 × 109/L. Although individuals with both high-count MBL and CLL Rai stage 0 are at increased risk of infections and second cancers, the risk of progression requiring treatment and the potential to shorten life expectancy are greater for CLL. This review highlights challenging questions regarding the classification, risk stratification, management, and supportive care of patients with MBL and CLL.

UR - http://www.scopus.com/inward/record.url?scp=84937847194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937847194&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-02-585059

DO - 10.1182/blood-2015-02-585059

M3 - Article

C2 - 26065657

AN - SCOPUS:84937847194

VL - 126

SP - 454

EP - 462

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -